Keros Therapeutics (NASDAQ:KROS) Earns Buy Rating from HC Wainwright
HC Wainwright reiterated their buy rating on shares of Keros Therapeutics (NASDAQ:KROS – Free Report) in a research report released on Tuesday, Benzinga reports. The brokerage currently has a $100.00 price target on the stock. Other analysts have also recently issued research reports about the stock. Truist Financial reissued a buy rating and issued a […]
More Stories
Bunzl plc (OTCMKTS:BZLFF) Short Interest Update
Bunzl plc (OTCMKTS:BZLFF – Get Free Report) saw a significant increase in short interest in the month of September. As...
Short Interest in Beach Energy Limited (OTCMKTS:BEPTF) Decreases By 7.1%
Beach Energy Limited (OTCMKTS:BEPTF – Get Free Report) was the recipient of a significant decrease in short interest in the...
Cost-Effective Strategies for Enhancing Workplace Safety and Reducing Injuries
Whether it is an office, factory, construction site or any other workplace, keeping employees safe and healthy should always be...
Short Interest in AddLife AB (publ) (OTCMKTS:ADDLF) Expands By 13.5%
AddLife AB (publ) (OTCMKTS:ADDLF – Get Free Report) saw a large growth in short interest during the month of September....
Short Interest in Alvopetro Energy Ltd. (OTCMKTS:ALVOF) Decreases By 8.9%
Alvopetro Energy Ltd. (OTCMKTS:ALVOF – Get Free Report) was the target of a large drop in short interest in September....
Athabasca Oil Co. (OTCMKTS:ATHOF) Short Interest Update
Athabasca Oil Co. (OTCMKTS:ATHOF – Get Free Report) was the target of a large increase in short interest in September....